Open AccessPhase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study
Author(s) -
Regina I. Jakacki,
Kenneth J. Cohen,
Allen Buxton,
Mark Krailo,
Peter C. Burger,
Marc K. Rosenblum,
Daniel J. Brat,
Ronald L. Hamilton,
Sandrah P. Eckel,
Tianni Zhou,
Robert S. Lavey,
Ian F. Pollack
Publication year - 2016
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/now038
Subject(s) - temozolomide , lomustine , medicine , glioma , radiation therapy , oligodendroglioma , oncology , astrocytoma , chemotherapy , vincristine , cancer research , cyclophosphamide
The prognosis for children with malignant glioma is poor. This study was designed to determine whether lomustine and temozolomide following radiotherapy and concurrent temozolomide improves event-free survival (EFS) compared with historical controls with anaplastic astrocytoma (AA) or glioblastoma (GBM) and whether survival is influenced by the expression of O6-methylguanine-DNA-methyltransferase (MGMT).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom